atezolizumab (Tecentriq)
Jump to navigation
Jump to search
Indications
- advanced bladder cancer (FDA-approved)*[1]
- neoadjuvant atezolizumab with gemcitabine & cisplatin in patients with muscle-invasive bladder cancer[8]
- non-small cell lung cancer after failure of or ineligibility for platinum-based chemotherapy[2]
- overall survival with atezolizumab is 10.3 months vs 9.2 months single-agent chemotherapy
- 2-year survival is 24% with atezolizumab vs 12% with chemotherapy[11]
- 1st line in combination with bevacizumab + carboplatin + paclitaxel for treatment of lung adenocarcinoma[4]
- maintenance therapy for metastatic small cell lung cancer
- in combination with bevacizumab for treatment of metastatic renal cell carcinoma*[3]
- treatment of unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1[5]
- liver cancer (FDA-approved)
- melanoma (FDA-approved)
* no longer FDA-approved in the U.S. for bladder or urinary tract cancer[9]
* continues FDA-approval for use in lung cancer, liver cancer & melanoma[9]
Dosage
Adverse effects
- most common
- serious
- immune-mediated adverse effects involving lung, colon & endocrine system[1]
- drug adverse effects of checkpoint inhibitor(s)
- drug adverse effects of pharmaceutical monoclonal antibodies
Laboratory
- Ventana PD-L1 (SP142) assay complementary diagnostic for Tecentriq
Mechanism of action
Notes
- cost ~ $12,500/month 2016[1]
More general terms
Additional terms
Component of
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 1.4 FDA News Release. May 18, 2016 FDA approves new, targeted treatment for bladder cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm
- ↑ Jump up to: 2.0 2.1 West HJ Should Atezolizumab Be the First-Choice Immunotherapy in Second-Line Non-Small Cell Lung Cancer? Medcape Oncology. Oct 31, 2016 http://www.medscape.com/viewarticle/871119
- ↑ Jump up to: 3.0 3.1 Fuerst ML with Expert Critique by Bowman IA Immunotherapy Plus Antiangiogenic Therapy Slows Growth of Advanced Kidney Cancer. Adding atezolizumab to bevacizumab delayed cancer growth by about 3 months longer than targeted therapy with sunitinib MedPage Today. 03.22.2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/71920
- ↑ Jump up to: 4.0 4.1 Smith M. NSCLC Survival Rises with Checkpoint Blocker Add-On Atezolizumab plus standard therapy also slows disease progression. MedPage Today. June 04, 2018 https://www.medpagetoday.com/meetingcoverage/asco/73280
Socinski MA, Jotte RM, Cappuzzo F et al Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29863955
Socinski MA et al Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. American Society of Clinical Oncology (ASCO) 2018; Abstract 9002 - ↑ Jump up to: 5.0 5.1 FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm
- ↑ Marin-Acevedo JA, Chirila RM, Dronca RS. Immune Checkpoint Inhibitor Toxicities. Mayo Clinic Proc. July 2019. 94(7):1321-1329 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31272574
- ↑ Davenport L Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC? Medscape. September 11, 2021 https://www.medscape.com/viewarticle/958588
- ↑ Jump up to: 8.0 8.1 Bassett M Pre-Op Atezolizumab Promising in Muscle-Invasive Bladder Cancer Over two-thirds downstaged to non-muscle-invasive disease with PD-L1 inhibitor plus chemotherapy. MedPage Today February 7, 2022 https://www.medpagetoday.com/hematologyoncology/othercancers/97053
Funt SA, Lattanzi M, Whiting K et al Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol. 2022. Jan 28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35089812 https://ascopubs.org/doi/abs/10.1200/JCO.21.01485 - ↑ Jump up to: 9.0 9.1 9.2 Chustecka Z Atezolizumab (Tecentriq) Bladder Cancer Indication Withdrawn in US. Medscape. Nov 29, 2022 https://www.medscape.com/viewarticle/984722
- ↑ Jump up to: 10.0 10.1 Hicks R NHS 'World First' Cancer Injection Roll-Out. Medscape UK. August 30, 2034 https://www.medscape.co.uk/viewarticle/nhs-world-first-cancer-injection-roll-out-2023a1000k5z
- ↑ Jump up to: 11.0 11.1 Lee SM et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum- containing regimen (IPSOS): A phase 3, global, multicentre, open-label, randomised controlled study. Lancet 2023 Aug 5; 402:451. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37423228 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00774-2/fulltext
- ↑ Medscape: atezolizumab (Rx) https://reference.medscape.com/drug/tecentriq-atezolizumab-1000098